Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Q1 2026 Overall Financial Performance
CRL logo

Charles River Laboratories Navigates Portfolio Shift With $995.8 Million In Revenue Despite Organic Decline

CRL8-KFiling Date: 5/7/2026
Charles River Laboratories International, Inc.
Description

What this story covers

Charles River Laboratories reported a complex Q1 2026, balancing a 1.5% organic revenue decline with strategic divestitures. Despite a GAAP loss from asset sales, the company reaffirmed full-year guidance, signaling confidence in its core drug development services.

Story snapshot

CompanyCharles River Laboratories International, Inc.
TickerCRL
VariantStandard detailed
Duration6:03
Filing type8-K
PeriodQ1 2026
IndustryHealthcare & Pharmaceuticals
Accession0001100682-26-000036
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing8-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in